Epidermal Growth Factor Receptor Stocks List
|2019-06-26||CKPT||Lower Bollinger Band Walk||Weakness|
|2019-06-26||CLVS||Stochastic Reached Oversold||Weakness|
|2019-06-26||MACK||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup|
|2019-06-26||MACK||Bollinger Band Squeeze||Range Contraction|
|2019-06-26||MACK||Crossed Above 20 DMA||Bullish|
|2019-06-26||MACK||Pocket Pivot||Bullish Swing Setup|
|2019-06-26||PBYI||Stochastic Reached Oversold||Weakness|
|2019-06-26||PBYI||New 52 Week Closing Low||Bearish|
|2019-06-26||PBYI||New 52 Week Low||Weakness|
|2019-06-26||PBYI||Expansion Breakdown||Bearish Swing Setup|
The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). In many cancer types, mutations affecting EGFR expression or activity could result in cancer.Epidermal growth factor and its receptor was discovered by Stanley Cohen of Vanderbilt University. Cohen shared the 1986 Nobel Prize in Medicine with Rita Levi-Montalcini for their discovery of growth factors.
Deficient signaling of the EGFR and other receptor tyrosine kinases in humans is associated with diseases such as Alzheimer's, while over-expression is associated with the development of a wide variety of tumors. Interruption of EGFR signalling, either by blocking EGFR binding sites on the extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent the growth of EGFR-expressing tumours and improve the patient's condition.